Lundbeck Presents Phase Ib Data for Parkinson's Drug Candidate
Lundbeck has presented initial safety and tolerability data from a Phase Ib trial of Lu AF28996 for advanced Parkinson's disease. The company has now commenced a Phase II study.
Lundbeck presented results from an 18-week, open-label Phase Ib trial of its investigational drug candidate Lu AF28996 in patients with advanced Parkinson's disease. The findings were shared at the MDS 2026 congress, providing initial data on the drug's safety and tolerability profile.
Most treatment-emergent adverse events reported in the trial were mild, according to the presented data. This study is part of Lundbeck's ongoing efforts to develop new therapeutic options for Parkinson's disease, a neurodegenerative disorder affecting motor functions.
To further assess the efficacy and safety of Lu AF28996, Lundbeck has initiated a Phase II clinical trial. This next phase of research aims to evaluate the drug's potential benefits in a larger patient population and determine optimal dosage.
Parkinson's disease affects millions worldwide, with current treatments primarily managing symptoms rather than halting disease progression. The development of new therapies like Lu AF28996 is critical for improving patient outcomes and quality of life.